Hana Biosciences, Tekmira deal

Tekmira will receive a $5.8 million payment from Hana to reduce future milestone payments owed to Tekmira under a 2006 deal. Hana has exclusive, worldwide rights to cancer compounds Marqibo vincristine, Alocrest vinorelbine and Brakiva topotecan liposomes injection under the deal. Concurrent with the reduction in milestones, Tekmira will pay former Tekmira debt holders $5.8 million to eliminate all future payments owed to the debt holders under a 2006 settlement. The debt holders were eligible for up to $22.8 million based on the milestone payments from Hana (see BioCentury, March 20, 2006). ...